• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测阿尔茨海默病进展模型的开发与验证

Development and validation of a model to predict the progression of Alzheimer's disease.

作者信息

Chu Chenyin, Wang Yihan, L H Huynh Andrew, Ng Ka Weng, Liu Shu, Ji Guangyan, Doecke James, Fripp Jurgen, Masters Colin L, Goudey Benjamin, Jin Liang, Pan Yijun

机构信息

Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.

Department of Medicine, Austin Health, Heidelberg, Victoria, Australia.

出版信息

Age Ageing. 2025 Jul 1;54(7). doi: 10.1093/ageing/afaf198.

DOI:10.1093/ageing/afaf198
PMID:40705053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12288498/
Abstract

BACKGROUND

Cognition monitoring is crucial for care planning in people with mild cognitive impairment (MCI) and Alzheimer's dementia (AD).

OBJECTIVE

To develop a machine learning model to assist cognition monitoring.

DESIGN

Florey Fusion Model (FFM) was constructed and validated in two phases: (i) model development and cross-validation using data collected via the Australian Imaging, Biomarker, and Lifestyle of Ageing (AIBL) study, and (ii) simulation and missing data trials with 30 new participants.

METHODS

This prognostic study recruited 238 participants in the AIBL study. Support vector machine, gradient boosting and random forest were trialled to develop the FFM. Cognitive decline was assessed via changes in Clinical Dementia Rating Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE) scores. Model performance was evaluated by cross validation and compared against baseline models.

RESULTS

The FFM achieved a median area under receive character curve (AUC-ROC) of 0.91 (IQR 0.87-0.93) for MCI-to-AD progression prediction. A mean absolute error (MAE) of 1.32 (IQR 1.30-1.33) for CDR-SB and 1.51 (IQR 1.50-1.52) for MMSE was achieved for 3-year cognition forecast. Simulation and missing data trials yielded up to 94% accuracy for MCI-to-AD conversion and MAEs of 1.27-2.12 for CDR-SB score prediction.

CONCLUSION

The FFM holds the potential to facilitate cognition monitoring in people with MCI/AD; however, a larger trial will be required to refine it as a clinical grade tool.

摘要

背景

认知监测对于轻度认知障碍(MCI)和阿尔茨海默病(AD)患者的护理规划至关重要。

目的

开发一种机器学习模型以辅助认知监测。

设计

弗洛里融合模型(FFM)分两个阶段构建和验证:(i)使用通过澳大利亚衰老成像、生物标志物和生活方式(AIBL)研究收集的数据进行模型开发和交叉验证,以及(ii)对30名新参与者进行模拟和缺失数据试验。

方法

这项预后研究在AIBL研究中招募了238名参与者。试用支持向量机、梯度提升和随机森林来开发FFM。通过临床痴呆评定框总和(CDR-SB)和简易精神状态检查表(MMSE)评分的变化评估认知衰退。通过交叉验证评估模型性能,并与基线模型进行比较。

结果

FFM在预测MCI向AD进展方面,接收特征曲线下面积(AUC-ROC)的中位数为0.91(四分位间距0.87-0.93)。在进行3年认知预测时,CDR-SB的平均绝对误差(MAE)为1.32(四分位间距1.30-1.33),MMSE为1.51(四分位间距1.50-1.52)。模拟和缺失数据试验在MCI向AD转化方面的准确率高达94%,在CDR-SB评分预测方面的MAE为1.27-2.12。

结论

FFM有潜力促进MCI/AD患者的认知监测;然而,需要更大规模的试验将其完善为临床级工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/709bf68f24a4/afaf198f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/c3bad46ddfff/afaf198f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/dc4e3be7cdeb/afaf198f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/709bf68f24a4/afaf198f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/c3bad46ddfff/afaf198f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/dc4e3be7cdeb/afaf198f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f89a/12288498/709bf68f24a4/afaf198f3.jpg

相似文献

1
Development and validation of a model to predict the progression of Alzheimer's disease.预测阿尔茨海默病进展模型的开发与验证
Age Ageing. 2025 Jul 1;54(7). doi: 10.1093/ageing/afaf198.
2
Extension and external validation of mapping between the Mini-Mental State Examination and the Clinical Dementia Rating scale in patients with Alzheimer's disease.阿尔茨海默病患者简易精神状态检查表与临床痴呆评定量表之间映射关系的扩展及外部验证
Alzheimers Dement. 2025 Jun;21(6):e70163. doi: 10.1002/alz.70163.
3
Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).用于检测轻度认知障碍(MCI)患者中阿尔茨海默病及其他痴呆症的简易精神状态检查表(MMSE)。
Cochrane Database Syst Rev. 2015 Mar 5;2015(3):CD010783. doi: 10.1002/14651858.CD010783.pub2.
4
Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage.预测认知衰退:深度学习揭示轻度认知障碍前阶段大脑的细微变化。
J Prev Alzheimers Dis. 2025 May;12(5):100079. doi: 10.1016/j.tjpad.2025.100079. Epub 2025 Feb 6.
5
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
6
Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum.血浆p217 + tau在阿尔茨海默病连续体中的两年预后效用
J Prev Alzheimers Dis. 2023;10(4):828-836. doi: 10.14283/jpad.2023.83.
7
Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia.预测轻度认知障碍和阿尔茨海默病性痴呆发病的工具的开发与验证
JAMA Netw Open. 2025 Jan 2;8(1):e2453756. doi: 10.1001/jamanetworkopen.2024.53756.
8
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
9
Impact of diabetes on the progression of Alzheimer's disease via trajectories of amyloid-tau-neurodegeneration (ATN) biomarkers.糖尿病通过淀粉样蛋白- tau-神经变性(ATN)生物标志物轨迹对阿尔茨海默病进展的影响。
J Nutr Health Aging. 2025 Feb;29(2):100444. doi: 10.1016/j.jnha.2024.100444. Epub 2024 Dec 10.
10
(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).(11)使用C-PIB-PET对轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆进行早期诊断。
Cochrane Database Syst Rev. 2014 Jul 23;2014(7):CD010386. doi: 10.1002/14651858.CD010386.pub2.

本文引用的文献

1
Leveraging mixed-effects regression trees for the analysis of high-dimensional longitudinal data to identify the low and high-risk subgroups: simulation study with application to genetic study.利用混合效应回归树分析高维纵向数据以识别低风险和高风险亚组:应用于基因研究的模拟研究
BioData Min. 2025 Mar 19;18(1):22. doi: 10.1186/s13040-025-00437-w.
2
A Comparison of an Australian Observational Longitudinal Alzheimer's Disease Cohort to Community-Based Australian Data.澳大利亚观察性纵向阿尔茨海默病队列与基于社区的澳大利亚数据比较。
J Alzheimers Dis. 2024;101(3):737-749. doi: 10.3233/JAD-240241.
3
Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians.
了解机器学习在痴呆症研究和临床实践中的应用:给生物医学科学家和临床医生的综述
Alzheimers Res Ther. 2024 Aug 1;16(1):175. doi: 10.1186/s13195-024-01540-6.
4
Technology Usability for People Living With Dementia: Concept Analysis.技术对痴呆症患者的可用性:概念分析。
JMIR Aging. 2024 Jul 3;7:e51987. doi: 10.2196/51987.
5
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.TRIPOD+AI 声明:报告使用回归或机器学习方法的临床预测模型的更新指南。
BMJ. 2024 Apr 16;385:e078378. doi: 10.1136/bmj-2023-078378.
6
Enhancing post-diagnostic care in Australian memory clinics: Health professionals' insights into current practices, barriers and facilitators, and desirable support.提高澳大利亚记忆诊所的诊断后护理水平:卫生专业人员对当前实践、障碍和促进因素以及所需支持的看法。
Dementia (London). 2024 Jan;23(1):109-131. doi: 10.1177/14713012231213419. Epub 2023 Nov 24.
7
How Can We Use Mathematical Modeling of Amyloid-β in Alzheimer's Disease Research and Clinical Practices?如何在阿尔茨海默病的研究和临床实践中应用淀粉样β的数学建模?
J Alzheimers Dis. 2024;97(1):89-100. doi: 10.3233/JAD-230938.
8
SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis.基于 SIMOA 的血浆 NFL 水平在 MCI 和 AD 患者中的分析:系统评价和荟萃分析。
BMC Neurol. 2023 Sep 18;23(1):331. doi: 10.1186/s12883-023-03377-2.
9
Practice effects in cognitive assessments three years later in non-carriers but not in symptom-free mutation carriers of autosomal-dominant Alzheimer's disease: Exemplifying procedural learning and memory?常染色体显性阿尔茨海默病无症状突变携带者三年后认知评估中的练习效应:程序性学习和记忆的例证?非携带者不存在该效应
Front Aging Neurosci. 2022 Oct 5;14:905329. doi: 10.3389/fnagi.2022.905329. eCollection 2022.
10
Nationally Informed Recommendations on Approaching the Detection, Assessment, and Management of Mild Cognitive Impairment.国家对轻度认知障碍的检测、评估和管理的建议
J Alzheimers Dis. 2022;89(3):803-809. doi: 10.3233/JAD-220288.